Correction to: All HER2-negative breast cancer patients need gBRCA testing: cost-effectiveness and clinical benefits

Huai-liang Wu; Zi-yin Luo; Zong-lin He; Yue Gong; Miao Mo; Wai-kit Ming; Guang-yu Liu

doi:10.1038/s41416-023-02159-4

Correction to: All HER2-negative breast cancer patients need gBRCA testing: cost-effectiveness and clinical benefits

Huai-liang Wu
, Zi-yin Luo
, Zong-lin He
, Yue Gong
, Miao Mo
, Wai-kit Ming
, Guang-yu Liu^*

^*Corresponding author for this work

Research output: Journal Publications and Reviews › Erratum

42 Downloads (CityUHK Scholars)

Abstract

Correction to: British Journal of Cancer https://doi.org/10.1038/s41416-022-02111-y, published online 23 December 2022

The original version of this article contained a mistake. The first affiliation should be changed to Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Department of Oncology, Fudan University Shanghai Cancer Center, Shanghai, China. The original article has been corrected. © 2023, The Author(s), under exclusive licence to Springer Nature Limited.

Original language	English
Article number	704
Journal	British Journal of Cancer
Volume	128
Issue number	4
Online published	30 Jan 2023
DOIs	https://doi.org/10.1038/s41416-023-02159-4
Publication status	Published - 16 Feb 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Publisher's Copyright Statement

This full text is made available under CC-BY 4.0. https://creativecommons.org/licenses/by/4.0/

Access Output

10.1038/s41416-023-02159-4

156270487.pdfFinal Published version, 218 KBLicence: CC BY

Other Access Options

Check CityUHK Library

Permanent Link

Right click to copy link

Cite this

@article{91a34de44d984b3091055c50a47c376c,

title = "Correction to: All HER2-negative breast cancer patients need gBRCA testing: cost-effectiveness and clinical benefits",

abstract = "Correction to: British Journal of Cancer https://doi.org/10.1038/s41416-022-02111-y, published online 23 December 2022 The original version of this article contained a mistake. The first affiliation should be changed to Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Department of Oncology, Fudan University Shanghai Cancer Center, Shanghai, China. The original article has been corrected. {\textcopyright} 2023, The Author(s), under exclusive licence to Springer Nature Limited.",

author = "Huai-liang Wu and Zi-yin Luo and Zong-lin He and Yue Gong and Miao Mo and Wai-kit Ming and Guang-yu Liu",

year = "2023",

month = feb,

day = "16",

doi = "10.1038/s41416-023-02159-4",

language = "English",

volume = "128",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Springer Nature",

number = "4",

}

TY - JOUR

T1 - Correction to: All HER2-negative breast cancer patients need gBRCA testing: cost-effectiveness and clinical benefits

AU - Wu, Huai-liang

AU - Luo, Zi-yin

AU - He, Zong-lin

AU - Gong, Yue

AU - Mo, Miao

AU - Ming, Wai-kit

AU - Liu, Guang-yu

PY - 2023/2/16

Y1 - 2023/2/16

N2 - Correction to: British Journal of Cancer https://doi.org/10.1038/s41416-022-02111-y, published online 23 December 2022 The original version of this article contained a mistake. The first affiliation should be changed to Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Department of Oncology, Fudan University Shanghai Cancer Center, Shanghai, China. The original article has been corrected. © 2023, The Author(s), under exclusive licence to Springer Nature Limited.

AB - Correction to: British Journal of Cancer https://doi.org/10.1038/s41416-022-02111-y, published online 23 December 2022 The original version of this article contained a mistake. The first affiliation should be changed to Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Department of Oncology, Fudan University Shanghai Cancer Center, Shanghai, China. The original article has been corrected. © 2023, The Author(s), under exclusive licence to Springer Nature Limited.

UR - https://www.scopus.com/pages/publications/85147031712

UR - https://www.scopus.com/record/pubmetrics.uri?eid=2-s2.0-85147031712&origin=recordpage

U2 - 10.1038/s41416-023-02159-4

DO - 10.1038/s41416-023-02159-4

M3 - Erratum

C2 - 36717677

SN - 0007-0920

VL - 128

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 4

M1 - 704

ER -

Correction to: All HER2-negative breast cancer patients need gBRCA testing: cost-effectiveness and clinical benefits

Abstract

UN SDGs

Publisher's Copyright Statement

Access Output

Other Access Options

Permanent Link

Other Files and Links

Fingerprint

All HER2-negative breast cancer patients need gBRCA testing: cost-effectiveness and clinical benefits

Cite this